论文部分内容阅读
一、据强森公司季刊“ZOO”报导,该公司新的中枢神经药Sabeluzole正在进行临床试验,有希望成为治疗与年龄有关的记忆损害疾病的药物。在50岁以上记忆功能低下病人中所做的一个双盲安慰剂对照试验中证明它对记忆功能有正的影响。除了形成新物质以外,它还明显地改善记忆信息的贮存。在第二个志愿者实验中,贮藏的信息的回忆有了改善,特別在记忆功能损害严重的病人
According to Johnson Quarterly Magazine, “ZOO” reported that Sabeluzole, the company’s new central nervous medicine, is undergoing clinical trials and hopes to become a drug for the treatment of age-related memory impairment diseases. A double-blind, placebo-controlled trial of patients with memory loss over 50 years of age demonstrated a positive effect on memory function. In addition to the formation of new substances, it also significantly improves the storage of memory information. In the second volunteer experiment, there was an improvement in the recall of stored information, especially in patients with impaired memory function